FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034349740> ?p ?o ?g. }

• W2034349740 endingPage "129" @default.
• W2034349740 startingPage "123" @default.
• W2034349740 abstract "Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment. The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control. We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4–120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between poorly controlled and partially or well controlled asthmatics showed a statistically significant higher prevalence of some comorbidities in the first group, namely obesity, gastro-oesophageal reflux disease (GORD), aspirin intolerance and mental disorders (all p < 0.001). Similarly, asthmatics with at least one exacerbation in the last year showed a significantly higher prevalence of obesity, chronic rhinosinusitis, nasal polyps, GORD, and aspirin intolerance (all p < 0.05) than patients without exacerbations. When we selected patients without relevant comorbidities (upper airways disease, GORD, obesity, aspirin intolerance) and not currently smoking (N = 73), the percentage of well or partially controlled asthmatics was significantly higher than in patients with comorbidities (84.9% vs 71.1%, p = 0.02); the rate of asthmatics without exacerbations in the last year was also higher (73.6% vs 51.1%, p = 0.001). During omalizumab treatment, a high percentage of asthmatics obtain a good or partial control of asthma. Comorbidities are associated with the lack of asthma control and persistence of exacerbations." @default.
• W2034349740 created "2016-06-24" @default.
• W2034349740 creator A5004032157 @default.
• W2034349740 creator A5004318668 @default.
• W2034349740 creator A5004866720 @default.
• W2034349740 creator A5014039023 @default.
• W2034349740 creator A5014181660 @default.
• W2034349740 creator A5017756139 @default.
• W2034349740 creator A5028035537 @default.
• W2034349740 creator A5030682932 @default.
• W2034349740 creator A5031776030 @default.
• W2034349740 creator A5037297396 @default.
• W2034349740 creator A5060089859 @default.
• W2034349740 creator A5085665455 @default.
• W2034349740 creator A5089497961 @default.
• W2034349740 date "2015-04-01" @default.
• W2034349740 modified "2023-10-17" @default.
• W2034349740 title "Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy" @default.
• W2034349740 cites W1974381613 @default.
• W2034349740 cites W1985951914 @default.
• W2034349740 cites W1986966401 @default.
• W2034349740 cites W2007459512 @default.
• W2034349740 cites W2029587541 @default.
• W2034349740 cites W2030415090 @default.
• W2034349740 cites W2033228689 @default.
• W2034349740 cites W2037071616 @default.
• W2034349740 cites W2051331973 @default.
• W2034349740 cites W2052012580 @default.
• W2034349740 cites W2060015303 @default.
• W2034349740 cites W2061775758 @default.
• W2034349740 cites W2073528727 @default.
• W2034349740 cites W2084213720 @default.
• W2034349740 cites W2084370208 @default.
• W2034349740 cites W2086347010 @default.
• W2034349740 cites W2099211356 @default.
• W2034349740 cites W2104718344 @default.
• W2034349740 cites W2106715003 @default.
• W2034349740 cites W2111033333 @default.
• W2034349740 cites W2128690134 @default.
• W2034349740 cites W2142637315 @default.
• W2034349740 cites W2152563928 @default.
• W2034349740 cites W2164111564 @default.
• W2034349740 cites W2164548578 @default.
• W2034349740 cites W2331277307 @default.
• W2034349740 cites W2994597783 @default.
• W2034349740 cites W4211006694 @default.
• W2034349740 doi "https://doi.org/10.1016/j.pupt.2014.09.007" @default.
• W2034349740 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25281265" @default.
• W2034349740 hasPublicationYear "2015" @default.
• W2034349740 type Work @default.
• W2034349740 sameAs 2034349740 @default.
• W2034349740 citedByCount "44" @default.
• W2034349740 countsByYear W20343497402015 @default.
• W2034349740 countsByYear W20343497402016 @default.
• W2034349740 countsByYear W20343497402017 @default.
• W2034349740 countsByYear W20343497402018 @default.
• W2034349740 countsByYear W20343497402019 @default.
• W2034349740 countsByYear W20343497402020 @default.
• W2034349740 countsByYear W20343497402021 @default.
• W2034349740 countsByYear W20343497402022 @default.
• W2034349740 countsByYear W20343497402023 @default.
• W2034349740 crossrefType "journal-article" @default.
• W2034349740 hasAuthorship W2034349740A5004032157 @default.
• W2034349740 hasAuthorship W2034349740A5004318668 @default.
• W2034349740 hasAuthorship W2034349740A5004866720 @default.
• W2034349740 hasAuthorship W2034349740A5014039023 @default.
• W2034349740 hasAuthorship W2034349740A5014181660 @default.
• W2034349740 hasAuthorship W2034349740A5017756139 @default.
• W2034349740 hasAuthorship W2034349740A5028035537 @default.
• W2034349740 hasAuthorship W2034349740A5030682932 @default.
• W2034349740 hasAuthorship W2034349740A5031776030 @default.
• W2034349740 hasAuthorship W2034349740A5037297396 @default.
• W2034349740 hasAuthorship W2034349740A5060089859 @default.
• W2034349740 hasAuthorship W2034349740A5085665455 @default.
• W2034349740 hasAuthorship W2034349740A5089497961 @default.
• W2034349740 hasBestOaLocation W20343497402 @default.
• W2034349740 hasConcept C126322002 @default.
• W2034349740 hasConcept C141105273 @default.
• W2034349740 hasConcept C142052008 @default.
• W2034349740 hasConcept C142724271 @default.
• W2034349740 hasConcept C159654299 @default.
• W2034349740 hasConcept C203014093 @default.
• W2034349740 hasConcept C23131810 @default.
• W2034349740 hasConcept C2776042228 @default.
• W2034349740 hasConcept C2777014526 @default.
• W2034349740 hasConcept C2777014857 @default.
• W2034349740 hasConcept C2777628954 @default.
• W2034349740 hasConcept C2778564945 @default.
• W2034349740 hasConcept C2779134260 @default.
• W2034349740 hasConcept C43270747 @default.
• W2034349740 hasConcept C511355011 @default.
• W2034349740 hasConcept C71924100 @default.
• W2034349740 hasConcept C90924648 @default.
• W2034349740 hasConceptScore W2034349740C126322002 @default.
• W2034349740 hasConceptScore W2034349740C141105273 @default.
• W2034349740 hasConceptScore W2034349740C142052008 @default.
• W2034349740 hasConceptScore W2034349740C142724271 @default.
• W2034349740 hasConceptScore W2034349740C159654299 @default.

• next